10.1 Leukotriene Modifiers & 5-Lipoxygenase Inhibitors

10.1 Leukotriene Modifiers & 5-Lipoxygenase Inhibitors

Quick Answer: Leukotriene modifiers are oral non-steroidal controller medications that target the 5-lipoxygenase inflammatory pathway. They comprise cysteinyl leukotriene receptor 1 (CysLT1) antagonists (montelukast, zafirlukast) and 5-lipoxygenase (5-LO) inhibitors (zileuton). While useful as add-on therapy for allergic asthma, exercise-induced bronchoconstriction (EIB), and Aspirin-Exacerbated Respiratory Disease (AERD), their use requires vigilance: montelukast carries a 2020 FDA Boxed Warning for serious neuropsychiatric events (agitation, depression, suicidal thinking), while zileuton requires mandatory baseline and periodic hepatic enzyme (ALT) surveillance due to hepatotoxicity.

While inhaled corticosteroids (ICS) suppress multiple inflammatory genes through transrepression of NF-κB and AP-1, they do not completely block the synthesis or physiological actions of cysteinyl leukotrienes. Cysteinyl leukotrienes are potent lipid mediators that drive airway smooth muscle contraction, microvascular leakage, mucus hypersecretion, and inflammatory cell recruitment. Consequently, leukotriene pathway modifiers occupy a vital therapeutic niche as alternative or adjunctive controller therapies in both the National Asthma Education and Prevention Program (NAEPP) and Global Initiative for Asthma (GINA) guidelines.

For the Certified Asthma Educator (AE-C), mastering this drug class requires detailed knowledge of arachidonic acid biochemistry, age-stratified dosing parameters, key clinical phenotypes, rigorous safety monitoring protocols, and specific strategies to identify adverse behavioral reactions.

---

Biochemical Pathway: Synthesis and Receptor Biology

Leukotrienes are generated from cell membrane phospholipids via the arachidonic acid cascade. When mast cells, eosinophils, basophils, or alveolar macrophages encounter inflammatory or allergic stimuli, cytosolic phospholipase A2 (cPLA2) hydrolyzes membrane phospholipids to liberate free arachidonic acid.

Arachidonic acid is then metabolized through two competing enzymatic pathways:

1. The Cyclooxygenase (COX) Pathway: Yields prostaglandins (PGE2, PGD2) and thromboxanes.
2. The 5-Lipoxygenase (5-LO) Pathway: Converted by the intracellular enzyme 5-lipoxygenase—in close association with 5-lipoxygenase-activating protein (FLAP)—into the unstable intermediate Leukotriene A4 (LTA4).

From LTA4, two distinct biological arms diverge:

• Leukotriene B4 (LTB4): Synthesized via LTA4 hydrolase. LTB4 acts on BLT1/BLT2 receptors and serves as a powerful chemoattractant and activator for neutrophils, promoting systemic leukocyte adhesion and degranulation.
• Cysteinyl Leukotrienes (LTC4, LTD4, LTE4): Synthesized when LTC4 synthase conjugates LTA4 with reduced glutathione. Extracellular peptidases subsequently cleave LTC4 into LTD4, which is further metabolized into the stable end-product LTE4.

                    Membrane Phospholipids
                              │
                              ▼ (Phospholipase A2)
                       Arachidonic Acid
                              │
          ┌───────────────────┴───────────────────┐
          ▼ (Cyclooxygenase)                      ▼ (5-LO + FLAP) [Inhibited by Zileuton]
    Prostaglandins &                            Leukotriene A4 (LTA4)
     Thromboxanes                                 │
                         ┌────────────────────────┴────────────────────────┐
                         ▼ (LTA4 Hydrolase)                                 ▼ (LTC4 Synthase)
                   Leukotriene B4 (LTB4)                            Leukotriene C4 (LTC4)
                 (Neutrophil Chemotaxis)                                   │
                                                                           ▼
                                                                    Leukotriene D4 (LTD4)
                                                                           │
                                                                           ▼
                                                                    Leukotriene E4 (LTE4)
                                                                           │
                                                                           ▼
                                                                   CysLT1 Receptor
                                                          [Blocked by Montelukast, Zafirlukast]
                                                                           │
                                                 ┌─────────────────────────┴─────────────────────────┐
                                                 ▼                                                   ▼
                                      Bronchoconstriction                                     Airway Edema &
                                    (1,000x > Histamine)                                   Mucus Hypersecretion

The CysLT1 Receptor

Cysteinyl leukotrienes bind primarily to the CysLT1 receptor located on human airway smooth muscle cells, interstitial macrophages, mast cells, and vascular endothelial cells. LTD4 exhibits the highest affinity for this receptor. Activation of CysLT1 triggers intracellular G-protein-coupled inositol trisphosphate (IP3) and calcium mobilization, producing:

• Extreme Bronchoconstriction: LTD4 is approximately 1,000 times more potent than histamine on a molar basis in contracting human bronchial smooth muscle.
• Microvascular Permeability: Promotes post-capillary venule plasma leakage, resulting in profound submucosal airway edema.
• Mucus Hypersecretion: Stimulates epithelial goblet cells and submucosal glands, increasing sputum volume and decreasing mucociliary clearance.
• Eosinophil Eosinotaxis: Recruits circulating eosinophils directly into the bronchial mucosa and prolongs their survival.

---

Pharmacological Classes: CysLT1 Antagonists vs. 5-LO Inhibitors

Leukotriene pathway modifiers fall into two distinct pharmacological classes with fundamentally different mechanisms of action:

1. Cysteinyl Leukotriene Receptor Antagonists (LTRAs)

LTRAs bind competitively and selectively to the CysLT1 receptor, preventing endogenous LTC4, LTD4, and LTE4 from exerting their pathophysiological effects. They have no inhibitory effect on 5-lipoxygenase enzyme activity, do not block LTB4 synthesis, and do not bind CysLT2 receptors.

• Montelukast (Singulair): The most widely prescribed leukotriene modifier. Administered once daily in the evening. Food does not significantly alter its absorption. It is available in three distinct age-appropriate formulations: 4 mg oral granules (approved for infants and children aged 6 to 23 months; can be dissolved in breast milk, infant formula, or mixed with applesauce/carrots/rice), 4 mg chewable tablets (ages 2 to 5 years), 5 mg chewable tablets (ages 6 to 14 years), and 10 mg film-coated tablets (adults and adolescents aged ≥15 years).
• Zafirlukast (Accolate): Approved for patients aged ≥5 years. Administered twice daily (10 mg BID for ages 5 to 11; 20 mg BID for ages ≥12). Unlike montelukast, zafirlukast must be taken on an empty stomach—at least 1 hour before or 2 hours after meals—because food decreases its bioavailability by approximately 40%.

2. 5-Lipoxygenase (5-LO) Inhibitors

• Zileuton (Zyflo, Zyflo CR): Directly and reversibly inhibits the 5-lipoxygenase enzyme by chelating the active-site ferric iron (Fe3+). Because it halts the cascade at the top of the pathway, zileuton blocks the biosynthesis of all downstream 5-LO metabolites—suppressing not only cysteinyl leukotrienes (LTC4, LTD4, LTE4) but also Leukotriene B4 (LTB4). Approved for patients aged ≥12 years. Formulated as an immediate-release tablet (600 mg four times daily) or extended-release tablet (Zyflo CR, 1,200 mg twice daily within 1 hour after morning and evening meals).

---

Leukotriene Pathway Modifiers Comparison

---

Distinct Clinical Phenotypes & Indications

While leukotriene modifiers produce less overall bronchodilation and anti-inflammatory protection than inhaled corticosteroids when used as monotherapy, they provide distinct clinical utility across three major phenotypes:

1. Allergic Asthma with Concomitant Allergic Rhinitis

Because cysteinyl leukotrienes mediate nasal mucosal congestion, rhinorrhea, and ocular itching alongside lower airway bronchoconstriction, LTRAs treat the upper and lower respiratory tracts simultaneously (the "unified airway" or "one-airway" concept). For patients struggling with both perennial/seasonal rhinitis and mild persistent asthma, montelukast monotherapy or combination therapy with an ICS significantly improves total nasal symptom scores and reduces daytime asthma symptoms.

2. Exercise-Induced Bronchoconstriction (EIB)

During strenuous physical exercise, hyperpnea causes thermal heat loss and evaporative water loss from the airway surface liquid. This osmotic dehydration triggers mast cell and basophil degranulation, releasing massive spikes of cysteinyl leukotrienes. A single oral dose of montelukast taken at least 2 hours prior to exercise provides significant protection against bronchoconstriction for up to 24 hours in approximately 50% of patients. Crucially, unlike daily long-acting beta-2 agonists (LABAs) or regular SABA use, tolerance (tachyphylaxis) does not develop with daily montelukast therapy for EIB. However, patients must understand that montelukast cannot reverse acute bronchospasm and must never replace a fast-acting rescue bronchodilator.

3. Aspirin-Exacerbated Respiratory Disease (AERD / Samter's Triad)

AERD is a non-IgE-mediated pseudoallergic syndrome characterized by the classic clinical triad: severe persistent asthma, chronic hyperplastic eosinophilic rhinosinusitis with recurrent nasal polyposis, and severe acute respiratory reactions upon ingesting aspirin or non-steroidal anti-inflammatory drugs (NSAIDs).

• Pathophysiology: In AERD, baseline expression of LTC4 synthase is markedly upregulated (up to 5-fold). Pharmacological inhibition of the COX-1 enzyme by aspirin or traditional NSAIDs eliminates the production of Prostaglandin E2 (PGE2). Under normal conditions, PGE2 exerts a continuous, brake-like inhibitory tone on 5-lipoxygenase. When COX-1 is blocked, PGE2 levels plummet, releasing the brake on 5-LO and shunting all available arachidonic acid into leukotriene synthesis. This triggers a catastrophic surge in cysteinyl leukotrienes, producing profound bronchoconstriction, laryngospasm, profuse rhinorrhea, and hypotension.
• Therapeutic Role: Both LTRAs (montelukast) and 5-LO inhibitors (zileuton) significantly improve baseline lung function, decrease nasal polyp recurrence, and reduce systemic corticosteroid dependency in AERD. Zileuton is uniquely potent in AERD because it suppresses both CysLTs and neutrophil-activating LTB4.

---

Safety Profile & The FDA Boxed Warning on Neuropsychiatric Events

The March 2020 FDA Boxed Warning (Montelukast)

In March 2020, following extensive review of post-marketing surveillance reports from the FDA Adverse Event Reporting System (FAERS) and observational studies, the U.S. Food and Drug Administration issued a Boxed Warning (Black Box Warning)—the agency's most prominent safety alert—for montelukast regarding serious neuropsychiatric (neuropsych) events.

Reported neuropsychiatric events span a wide spectrum of behavioral and psychological disturbances:

• Sleep disturbances: Vivid dreams, nightmares, insomnia, somnambulism (sleepwalking).
• Behavioral changes: Agitation, aggressive behavior or hostility, irritability, restlessness, anxiety.
• Psychiatric manifestations: Depression, dysphoria, obsessive-compulsive symptoms, hallucinations, disorientation.
• Severe suicidality: Suicidal ideation, suicide attempts, and completed suicide.

These reactions occur in pediatric, adolescent, and adult patients. While the exact biochemical mechanism remains under investigation, montelukast crosses the blood-brain barrier and binds to CysLT1 receptors present in microglial cells and neurons within the limbic system, potentially altering central monoaminergic neurotransmission.

Counselor Protocol for Montelukast Counseling & Surveillance

Certified Asthma Educators must execute a standardized counseling protocol before initiation and during every follow-up visit:

[Pre-Prescription Assessment]
  │  • Screen for baseline anxiety, depression, sleep disorders, or behavioral challenges.
  │  • Assess whether milder allergic rhinitis symptoms can be managed with intranasal steroids alone.
  ▼
[Mandatory Patient & Caregiver Education]
  │  • Explicitly name the Boxed Warning in clear, non-alarmist language.
  │  • Provide the official FDA Medication Guide at dispensing.
  │  • Emphasize that symptoms can occur at ANY time during therapy (within days or after months).
  ▼
[Action Plan for Neuropsychiatric Symptoms]
  │  • Instruct patient/caregiver to STOP montelukast IMMEDIATELY if behavior changes occur.
  │  • Contact the prescribing provider right away to report the reaction.
  │  • Never restart the medication if neuropsychiatric symptoms have occurred.
  ▼
[Pharmacovigilance Reporting]
     • Document the reaction and report to the FDA MedWatch program.

1. Pre-Prescription Risk Stratification: Inquire about pre-existing psychiatric disorders, depression, severe anxiety, or behavioral disturbances. In patients with mild allergic rhinitis, recommend first-line intranasal corticosteroids over montelukast to avoid unnecessary neuropsychiatric risk.
2. Transparent Caregiver Disclosure: Educate parents and caregivers using direct language: "Montelukast is an effective oral medicine for asthma, but the FDA requires a special black box warning because it can cause mood and behavior changes. In children and adults, it can cause bad nightmares, irritability, sudden aggression, sadness, or sleepwalking. In rare cases, it can cause thoughts of self-harm."
3. The Immediate Discontinuation Protocol: Instruct caregivers: "If you notice ANY unusual change in your child's behavior, sleep patterns, or mood—even subtle irritability or vivid nightmares—stop giving the medication immediately and call our clinic. Do not wait for the next scheduled appointment."
4. Reversibility and Follow-up: Symptoms typically resolve within days to weeks following drug discontinuation, although persistence has been documented in rare instances. Patients experiencing severe depression or suicidality require immediate behavioral health crisis intervention.

---

Hepatic Safety & Laboratory Monitoring Requirements (Zileuton)

Zileuton exhibits significant dose-dependent hepatotoxicity and can induce acute drug-induced liver injury (DILI). In clinical trials, approximately 3% to 4% of patients receiving zileuton experienced marked elevations in serum alanine aminotransferase (ALT) to greater than three times the upper limit of normal (ULN).

Mandatory Laboratory Protocol for Zileuton

• Baseline Testing: Serum ALT, AST, and total bilirubin must be obtained prior to initiating zileuton therapy. Therapy should not be started if baseline ALT is ≥3 times the ULN.
• Active Surveillance Schedule: Serum ALT must be monitored monthly for the first 3 months of therapy, then every 2 to 3 months for the remainder of the first year, and periodically thereafter for patients remaining on long-term treatment.
• Discontinuation Criteria: If serum transaminases (ALT/AST) rise to ≥5 times the upper limit of normal, or if the patient develops clinical symptoms of hepatic dysfunction (jaundice, pruritus, right upper quadrant abdominal pain, dark tea-colored urine, clay-colored stools, fatigue, or anorexia), zileuton must be discontinued immediately.

---

Cytochrome P450 Drug-Drug Interactions

Leukotriene modifiers undergo extensive hepatic metabolism through cytochrome P450 (CYP) enzymes, giving rise to clinically significant drug-drug interactions:

1. Zileuton (CYP1A2 Inhibition):

   • Theophylline: Zileuton is a potent inhibitor of CYP1A2. Co-administration with theophylline results in approximately a 100% increase (doubling) of serum theophylline concentrations, precipitating acute theophylline toxicity (seizures, tachyarrhythmias). If co-administered, the theophylline dose must be reduced by approximately 50%, and serum theophylline levels must be rigorously monitored.
   • Warfarin: Zileuton significantly increases the pharmacokinetic area under the curve (AUC) of R-warfarin, causing a marked elevation in prothrombin time and International Normalized Ratio (INR). Frequent INR monitoring and warfarin dosage reductions are mandatory.
   • Propranolol: Zileuton doubles propranolol AUC, increasing the risk of profound bradycardia and bronchospasm.

2. Zafirlukast (CYP2C9 and CYP3A4 Inhibition):

   • Warfarin: Zafirlukast strongly inhibits CYP2C9, the primary metabolic pathway for the active S-enantiomer of warfarin. Co-administration can cause dramatic, life-threatening increases in prothrombin time/INR and catastrophic hemorrhage. Prothrombin time must be monitored closely, and warfarin doses adjusted accordingly.
   • Theophylline: Zafirlukast increases plasma theophylline concentrations by approximately 30%. Conversely, theophylline co-administration decreases zafirlukast plasma levels by ~30%.
   • Aspirin: Co-administration of high-dose aspirin increases zafirlukast plasma levels by ~80% due to protein displacement and metabolic competition.

3. Montelukast:

   • Montelukast is primarily metabolized by CYP3A4, CYP2C8, and CYP2C9. It does not significantly inhibit these enzymes at therapeutic doses. Potent CYP inducers (phenobarbital, rifampin, carbamazepine, phenytoin) can decrease montelukast plasma levels by ~40%, though routine dosage adjustments are generally not recommended.